OncoImmunology (Dec 2022)

BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells

  • Hannes Forkel,
  • Piotr Grabarczyk,
  • Maren Depke,
  • Sascha Troschke-Meurer,
  • Stefan Simm,
  • Elke Hammer,
  • Stephan Michalik,
  • Christian Hentschker,
  • Björn Corleis,
  • Lucie Loyal,
  • Maxi Zumpe,
  • Nikolai Siebert,
  • Anca Dorhoi,
  • Andreas Thiel,
  • Holger Lode,
  • Uwe Völker,
  • Christian A. Schmidt

DOI
https://doi.org/10.1080/2162402X.2022.2148850
Journal volume & issue
Vol. 11, no. 1

Abstract

Read online

ABSTRACTBCL11B, an essential transcription factor for thymopoiesis, regulates also vital processes in post-thymic lymphocytes. Increased expression of BCL11B was recently correlated with the maturation of NK cells, whereas reduced BCL11B levels were observed in native and induced T cell subsets displaying NK cell features. We show that BCL11B-depleted CD8+ T cells stimulated with IL-15 acquired remarkable innate characteristics. These induced innate CD8+ (iiT8) cells expressed multiple innate receptors like NKp30, CD161, and CD16 as well as factors regulating migration and tissue homing while maintaining their T cell phenotype. The iiT8 cells effectively killed leukemic cells spontaneously and neuroblastoma spheroids in the presence of a tumor-specific monoclonal antibody mediated by CD16 receptor activation. These iiT8 cells integrate the innate natural killer cell activity with adaptive T cell longevity, promising an interesting therapeutic potential. Our study demonstrates that innate T cells, albeit of limited clinical applicability given their low frequency, can be efficiently generated from peripheral blood and applied for adoptive transfer, CAR therapy, or combined with therapeutic antibodies.

Keywords